Month: June 2026

The 2026 Congress of the European Hematology Association (EHA 2026), held from June 11–14 in Stockholm, Sweden, brought together leading experts from around the world to showcase the latest advances in hematology research, translational medicine, and clinical practice.

At the 2026 Congress of the European Hematology Association (EHA 2026), the team led by Professor Qian Jiang from Peking University People’s Hospital presented several important studies addressing key challenges in chronic myeloid leukemia (CML), including the biological heterogeneity of accelerated-phase disease and predictors of treatment-free remission (TFR).

The 2026 Congress of the European Hematology Association (EHA 2026) was held from June 11 to 14 in Stockholm, Sweden. As one of the most influential international meetings in hematology, EHA brings together leading experts from around the world to showcase the latest advances in basic science, translational research, and clinical practice.

As the 2026 Congress of the European Hematology Association (EHA 2026) prepares to open in Stockholm, Sweden, the global hematology community is once again gathering to share the latest scientific advances and shape the future of blood disease research and treatment.

The rapid emergence of CAR-T cell therapies and bispecific antibodies has transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM), leading to substantial improvements in patient outcomes. However, limitations related to accessibility, treatment costs, manufacturing complexity, and toxicity management continue to restrict their widespread use. As a result, there remains a pressing need for innovative therapies that combine efficacy, safety, and broad clinical applicability.

As part of its special ASCO 2026 coverage series, “China Perspectives at ASCO,” Oncology Frontier – Hematology Frontier invited leading Chinese experts to interpret the most practice-changing research presented at this year’s meeting and discuss its relevance to clinical practice in China.

Despite significant advances in recent years, the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) continues to present major clinical challenges. Existing therapies offer limited efficacy for many patients, particularly those with high-risk disease, highlighting a substantial unmet medical need.